Comparative Effectiveness May Be Next Battleground For First Amendment Fight With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Lawyers suggest new avenue to challenge restrictions on off-label information; also say FDA appears to be doubling down in rejecting observational studies and comparative analyses.
You may also be interested in...
FDA Scales Back Near-Term Goals For Sentinel Postmarket Data Network
FDA’s Janet Woodcock said the agency has not been able to overcome budgetary restrictions that hamper previously discussed plans to develop the Sentinel postmarket drug safety surveillance system into a much broader national resource.
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.